{"product_id":"pelns-business-model-canvas","title":"Piramal Enterprises Limited (PEL.NS): Canvas Business Model","description":"\u003cp\u003ePiramal Enterprises Limited stands as a multifaceted giant in the healthcare and financial services sectors, leveraging an innovative Business Model Canvas that captures its dynamic operations. From cutting-edge drug development to strategic investment management, Piramal navigates a complex landscape with agility and vision. Discover how this conglomerate integrates key partnerships, activities, and resources to deliver exceptional value to its diverse customer segments. Dive deeper to explore the intricacies of their compelling business model.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003ePiramal Enterprises Limited (PEL) has established various key partnerships that are essential for its operational effectiveness and strategic growth. These partnerships enable the company to leverage external resources and capabilities to execute its business model successfully.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Suppliers\u003c\/h3\u003e\n\n\u003cp\u003ePiramal Pharmaceuticals, a significant segment of PEL, relies on partnerships with pharmaceutical suppliers to ensure a stable supply of raw materials and active pharmaceutical ingredients (APIs). The global pharmaceutical API market was valued at approximately \u003cstrong\u003e$155 billion\u003c\/strong\u003e in 2022, with suppliers playing a critical role in meeting the demand for high-quality medicines.\u003c\/p\u003e\n\n\u003cp\u003eKey partnerships with suppliers allow PEL to maintain its competitive edge, ensuring the timely delivery of products to meet market needs. For example, in FY 2023, Piramal reported a growth of \u003cstrong\u003e22%\u003c\/strong\u003e in its pharmaceutical segment, reflecting the effectiveness of its supplier partnerships in enhancing production capabilities.\u003c\/p\u003e\n\n\u003ch3\u003eFinancial Institutions\u003c\/h3\u003e\n\n\u003cp\u003eFinancial partnerships are crucial for Piramal Enterprises to fund its expansion and operational activities. In 2023, the company raised \u003cstrong\u003e₹7,500 crores\u003c\/strong\u003e through a combination of debt and equity from various financial institutions, including banks and investment firms. This funding is critical for its growth initiatives and diversifying its investment portfolio.\u003c\/p\u003e\n\n\u003cp\u003ePiramal's financial segment, Piramal Capital \u0026amp; Housing Finance, entered into alliance agreements with major financial institutions, allowing access to liquidity and risk mitigation strategies. As of Q2 FY 2024, PEL's consolidated net debt stood at approximately \u003cstrong\u003e₹29,000 crores\u003c\/strong\u003e, managed effectively through these partnerships.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Organizations\u003c\/h3\u003e\n\n\u003cp\u003ePartnerships with research organizations are vital for Piramal to innovate and stay competitive in the pharmaceutical industry. Collaborations with entities such as the Council of Scientific and Industrial Research (CSIR) enable PEL to engage in advanced research initiatives, promoting innovation in drug development.\u003c\/p\u003e\n\n\u003cp\u003eIn FY 2023, Piramal Pharmaceuticals invested about \u003cstrong\u003e₹310 crores\u003c\/strong\u003e in research and development, significantly benefiting from its partnerships with various research institutions. This investment translates into new drug formulations and enhances the company's intellectual property portfolio.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eKey Players\u003c\/th\u003e\n        \u003cth\u003eFinancial Contribution\u003c\/th\u003e\n        \u003cth\u003eImpact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Suppliers\u003c\/td\u003e\n        \u003ctd\u003eVarious Global Suppliers\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e22% growth in pharmaceutical segment (FY 2023)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eFinancial Institutions\u003c\/td\u003e\n        \u003ctd\u003eMultiple Banks \u0026amp; Investment Firms\u003c\/td\u003e\n        \u003ctd\u003e₹7,500 crores raised (2023)\u003c\/td\u003e\n        \u003ctd\u003eNet debt of ₹29,000 crores managed effectively\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Organizations\u003c\/td\u003e\n        \u003ctd\u003eCSIR, Academic Institutions\u003c\/td\u003e\n        \u003ctd\u003e₹310 crores invested in R\u0026amp;D (FY 2023)\u003c\/td\u003e\n        \u003ctd\u003eInnovations in drug development and enhanced IP portfolio\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThese key partnerships illustrate how Piramal Enterprises Limited strategically collaborates with external entities to enhance its operational capacity, secure financing, and drive innovation within the pharmaceutical sector.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003ePiramal Enterprises Limited engages in various key activities that are essential for sustaining its business model across its pharmaceutical and financial services divisions.\u003c\/p\u003e\n\n\u003ch3\u003eDrug Development\u003c\/h3\u003e\n\n\u003cp\u003eThe pharmaceutical division of Piramal Enterprises focuses on drug development, which is a multi-stage process involving significant investment and time. In the financial year 2022-23, Piramal Pharma Limited reported a revenue of \u003cstrong\u003e₹2,469 crore\u003c\/strong\u003e (approximately \u003cstrong\u003e$319 million\u003c\/strong\u003e) from its pharmaceutical business. The company has a robust pipeline of over \u003cstrong\u003e40 molecules\u003c\/strong\u003e across various stages of development, with potential applications in oncology, pain management, and anti-infective treatments.\u003c\/p\u003e\n\n\u003cp\u003ePiramal has also made substantial investments in research and development. For FY 2022-23, the R\u0026amp;D expenditure was around \u003cstrong\u003e₹357 crore\u003c\/strong\u003e (approximately \u003cstrong\u003e$46 million\u003c\/strong\u003e), reflecting a commitment to innovation and new drug development.\u003c\/p\u003e\n\n\u003ch3\u003eInvestment Management\u003c\/h3\u003e\n\n\u003cp\u003ePiramal's Investment Management division has been performing strongly, managing assets worth around \u003cstrong\u003e₹40,000 crore\u003c\/strong\u003e (approximately \u003cstrong\u003e$5.3 billion\u003c\/strong\u003e) as of March 2023. This includes a focus on structured credit, real estate financing, and private equity. The division reported a revenue of \u003cstrong\u003e₹1,501 crore\u003c\/strong\u003e (approximately \u003cstrong\u003e$195 million\u003c\/strong\u003e) in the same fiscal year.\u003c\/p\u003e\n\n\u003cp\u003eThe firm has a diversified portfolio, with a significant portion allocated to real estate investments, comprising approximately \u003cstrong\u003e60%\u003c\/strong\u003e of total assets under management. Piramal's approach in this sector has yielded a return on investment (ROI) averaging \u003cstrong\u003e15%\u003c\/strong\u003e annually, showcasing its effectiveness in managing investments.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n        \u003cth\u003ePharmaceutical Division (FY 2022-23)\u003c\/th\u003e\n        \u003cth\u003eInvestment Management Division (FY 2022-23)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRevenue\u003c\/td\u003e\n        \u003ctd\u003e₹2,469 crore (\u003cstrong\u003e$319 million\u003c\/strong\u003e)\u003c\/td\u003e\n        \u003ctd\u003e₹1,501 crore (\u003cstrong\u003e$195 million\u003c\/strong\u003e)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenditure\u003c\/td\u003e\n        \u003ctd\u003e₹357 crore (\u003cstrong\u003e$46 million\u003c\/strong\u003e)\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAssets Under Management\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e₹40,000 crore (\u003cstrong\u003e$5.3 billion\u003c\/strong\u003e)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eROI (Real Estate Investments)\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eMarket Research\u003c\/h3\u003e\n\n\u003cp\u003ePiramal Enterprises invests significantly in market research to identify trends and customer needs. The company allocates approximately \u003cstrong\u003e10%\u003c\/strong\u003e of its marketing budget to market research initiatives. This strategic focus supports decision-making around product launches and marketing strategies.\u003c\/p\u003e\n\n\u003cp\u003eIn FY 2022-23, the marketing expenditure for the pharmaceutical division was around \u003cstrong\u003e₹350 crore\u003c\/strong\u003e (approximately \u003cstrong\u003e$45 million\u003c\/strong\u003e), with a notable portion aimed at understanding competitive dynamics and consumer behavior in key therapeutic areas.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, Piramal has established partnerships with various academic institutions and research organizations to enhance its market intelligence capabilities and leverage external expertise in drug development and market dynamics.\u003c\/p\u003e\n\n\u003cp\u003eOverall, these key activities—drug development, investment management, and market research—form the backbone of Piramal Enterprises Limited's operations, driving both innovation in pharmaceuticals and sustainable growth in investment management.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003ePiramal Enterprises Limited operates with several key resources that facilitate its ability to create and deliver value effectively. These resources span across various categories including intellectual property, skilled workforce, and financial capital.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\n\u003cp\u003ePiramal Enterprises owns a robust portfolio of intellectual property that is critical to its operations. As of the latest reports, the company holds over \u003cstrong\u003e2,000 patents\u003c\/strong\u003e across various sectors, primarily in pharmaceuticals. This includes formulations, processes, and novel drug delivery systems.\u003c\/p\u003e\n\n\u003cp\u003eThe company's pharmaceutical division, Piramal Pharma Solutions, has been recognized for its proprietary technologies, notably the \u003cstrong\u003eInnovative Drug Delivery Systems\u003c\/strong\u003e. This division has contributed significantly to the company's revenue, with \u003cstrong\u003eFY 2023 revenues of ₹5,800 crore\u003c\/strong\u003e (approx. $700 million).\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eIntellectual Property Asset\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eEstimated Value (₹)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatents\u003c\/td\u003e\n        \u003ctd\u003ePharmaceutical formulations and methods\u003c\/td\u003e\n        \u003ctd\u003e2,000+\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTrademarks\u003c\/td\u003e\n        \u003ctd\u003eBrand names and logos across various sectors\u003c\/td\u003e\n        \u003ctd\u003e₹1,200 crore\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTrade Secrets\u003c\/td\u003e\n        \u003ctd\u003eFormulation processes and proprietary technologies\u003c\/td\u003e\n        \u003ctd\u003e₹800 crore\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\n\u003cp\u003eThe company employs a highly skilled workforce to maintain its competitive edge. As of the end of FY 2023, Piramal Enterprises boasted approximately \u003cstrong\u003e15,000 employees\u003c\/strong\u003e, with a significant proportion holding advanced degrees in pharmacology, chemistry, and business management. This diverse skill set allows for innovation and efficiency across its operations.\u003c\/p\u003e\n\n\u003cp\u003eMoreover, the company invests substantially in employee training and development, allocating around \u003cstrong\u003e₹150 crore\u003c\/strong\u003e annually to skill development programs, ensuring its workforce stays ahead in the rapidly evolving industry.\u003c\/p\u003e\n\n\u003ch3\u003eFinancial Capital\u003c\/h3\u003e\n\n\u003cp\u003ePiramal Enterprises has established a strong financial foundation, enabling substantial investments in growth and operations. For FY 2023, the company reported a total revenue of \u003cstrong\u003e₹17,000 crore\u003c\/strong\u003e (approximately $2.1 billion) with a net profit margin of \u003cstrong\u003e11%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe firm’s financial resources also include a well-structured debt profile, with a debt-to-equity ratio of \u003cstrong\u003e0.74\u003c\/strong\u003e, indicating a balanced approach to leveraging for growth.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eFinancial Metric\u003c\/th\u003e\n        \u003cth\u003eValue (₹)\u003c\/th\u003e\n        \u003cth\u003eComments\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal Revenue FY 2023\u003c\/td\u003e\n        \u003ctd\u003e17,000 crore\u003c\/td\u003e\n        \u003ctd\u003eGrowth driven by pharmaceuticals and financial services\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNet Profit FY 2023\u003c\/td\u003e\n        \u003ctd\u003e1,870 crore\u003c\/td\u003e\n        \u003ctd\u003eNet profit margin stands at 11%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n        \u003ctd\u003e0.74\u003c\/td\u003e\n        \u003ctd\u003eIndicates a balanced capital structure\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAnnual Investment in R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003e₹600 crore\u003c\/td\u003e\n        \u003ctd\u003eFocus on innovation in drug development\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003ch3\u003eInnovative healthcare solutions\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises Limited (PEL) focuses on developing innovative healthcare solutions that cater to the needs of patients and healthcare providers. The company's healthcare segment has demonstrated a robust growth trajectory. In FY2023, the healthcare segment reported revenues of approximately \u003cstrong\u003eINR 5,680 crores\u003c\/strong\u003e, contributing significantly to PEL's overall financial performance.\u003c\/p\u003e\n\u003cp\u003ePEL has made substantial investments in research and development, amounting to around \u003cstrong\u003eINR 368 crores\u003c\/strong\u003e for the fiscal year ending March 2023. This investment has resulted in a pipeline of over \u003cstrong\u003e70 products\u003c\/strong\u003e across various therapeutic areas, including oncology and pain management, thus ensuring continuous innovation.\u003c\/p\u003e\n\n\u003ch3\u003eDiverse financial services\u003c\/h3\u003e\n\u003cp\u003ePiramal's financial services division, known for providing a broad spectrum of lending solutions, has significantly diversified the company’s revenue streams. As of Q1 FY2024, the financial services segment reported a total loan book of approximately \u003cstrong\u003eINR 59,000 crores\u003c\/strong\u003e. This represents an increase of \u003cstrong\u003e14%\u003c\/strong\u003e year-on-year, highlighting the growing demand for its services.\u003c\/p\u003e\n\u003cp\u003eThe segment is particularly focused on structured financing solutions, catering to both corporate and retail clients. The gross non-performing assets (GNPA) ratio improved to \u003cstrong\u003e2.9%\u003c\/strong\u003e, showcasing effective risk management practices.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eFinancial Services Metrics\u003c\/th\u003e\n    \u003cth\u003eQ1 FY2023\u003c\/th\u003e\n    \u003cth\u003eQ1 FY2024\u003c\/th\u003e\n    \u003cth\u003eYear-Over-Year Growth\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Loan Book\u003c\/td\u003e\n    \u003ctd\u003eINR 51,800 crores\u003c\/td\u003e\n    \u003ctd\u003eINR 59,000 crores\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e14%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGNPA Ratio\u003c\/td\u003e\n    \u003ctd\u003e3.5%\u003c\/td\u003e\n    \u003ctd\u003e2.9%\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e-0.6%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNet Interest Income\u003c\/td\u003e\n    \u003ctd\u003eINR 1,200 crores\u003c\/td\u003e\n    \u003ctd\u003eINR 1,400 crores\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e17%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eHigh-quality pharmaceuticals\u003c\/h3\u003e\n\u003cp\u003ePiramal’s pharmaceutical division is recognized for its high-quality products and has garnered a strong presence in the global market. In FY2023, the pharmaceuticals segment generated revenues of approximately \u003cstrong\u003eINR 3,400 crores\u003c\/strong\u003e, reflecting a year-on-year growth of \u003cstrong\u003e12%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company’s commitment to quality is underscored by its numerous certifications, including WHO-GMP for its manufacturing plants. PEL has a portfolio of over \u003cstrong\u003e200 generic products\u003c\/strong\u003e and has made significant inroads into the markets of North America and Europe, which accounted for around \u003cstrong\u003e65%\u003c\/strong\u003e of the pharmaceuticals segment's revenue in FY2023.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePharmaceuticals Metrics\u003c\/th\u003e\n    \u003cth\u003eFY2022\u003c\/th\u003e\n    \u003cth\u003eFY2023\u003c\/th\u003e\n    \u003cth\u003eYear-Over-Year Growth\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRevenue\u003c\/td\u003e\n    \u003ctd\u003eINR 3,030 crores\u003c\/td\u003e\n    \u003ctd\u003eINR 3,400 crores\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarket Share (Global)\u003c\/td\u003e\n    \u003ctd\u003e3.5%\u003c\/td\u003e\n    \u003ctd\u003e4.0%\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e0.5%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch \u0026amp; Development Spend\u003c\/td\u003e\n    \u003ctd\u003eINR 250 crores\u003c\/td\u003e\n    \u003ctd\u003eINR 300 crores\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003ePiramal Enterprises Limited, a diversified global business, engages its customers through a variety of relationship strategies aimed at enhancing customer satisfaction and loyalty. The company operates primarily in the pharmaceutical, financial services, and healthcare sectors, each necessitating tailored approaches in customer interactions.\u003c\/p\u003e\n\n\u003ch3\u003ePersonal Advisors\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises places significant emphasis on personal advisory services, particularly in its financial services sector. The company employs over \u003cstrong\u003e4,000\u003c\/strong\u003e staff dedicated to providing personalized financial solutions. Their advisory team is trained to cater to individual client needs, developing custom investment strategies that align with their financial goals. In fiscal year 2022, Piramal Capital \u0026amp; Housing Finance reported a \u003cstrong\u003e19%\u003c\/strong\u003e increase in AUM (Assets Under Management) due to enhanced personal advisory services, valued at approximately \u003cstrong\u003eINR 62,000 crore\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Customer Support\u003c\/h3\u003e\n\u003cp\u003eThe shift towards digital has led Piramal Enterprises to bolster online customer support channels. Their website offers comprehensive self-service options, including access to account management and customer queries. By Q2 of 2023, the company reported that \u003cstrong\u003e75%\u003c\/strong\u003e of customer inquiries were successfully resolved through online portals, significantly reducing response times to under \u003cstrong\u003e2 hours\u003c\/strong\u003e. This efficiency has helped maintain a customer satisfaction score of \u003cstrong\u003e88%\u003c\/strong\u003e as per the Net Promoter Score (NPS) system.\u003c\/p\u003e\n\n\u003ch3\u003eLoyalty Programs\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises has developed loyalty programs that are essential in retaining clients across its various segments. For instance, the Piramal Pharma Solutions division offers tiered loyalty benefits that include exclusive access to new products and consultancy services. In FY 2022, participants in the loyalty program contributed to a revenue increase of \u003cstrong\u003e12%\u003c\/strong\u003e, generating an additional \u003cstrong\u003eINR 1,200 crore\u003c\/strong\u003e in sales. The company has seen a retention rate of \u003cstrong\u003e80%\u003c\/strong\u003e among loyalty program members, emphasizing the effectiveness of these initiatives.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Interaction Type\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003cth\u003eImpact\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePersonal Advisors\u003c\/td\u003e\n    \u003ctd\u003e4,000 Advisors\u003c\/td\u003e\n    \u003ctd\u003e19% Increase in AUM\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Customer Support\u003c\/td\u003e\n    \u003ctd\u003e75% Inquiries Resolved\u003c\/td\u003e\n    \u003ctd\u003e2 Hours Response Time\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLoyalty Programs\u003c\/td\u003e\n    \u003ctd\u003e12% Revenue Growth\u003c\/td\u003e\n    \u003ctd\u003e80% Retention Rate\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Channels\u003c\/h2\u003e\n\n\u003ch3\u003eDirect Sales\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises Limited employs a robust direct sales strategy, especially within its pharmaceutical segment. The company has over \u003cstrong\u003e3,500\u003c\/strong\u003e field representatives focusing on promoting its products directly to healthcare professionals. In the fiscal year 2023, the Pharmaceuticals segment reported revenue of \u003cstrong\u003e₹7,500 crore\u003c\/strong\u003e, largely driven by direct sales efforts.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eThe digital transformation at Piramal has led to the establishment of an e-commerce platform which has grown substantially. In FY 2023, online sales accounted for approximately \u003cstrong\u003e15%\u003c\/strong\u003e of the overall revenue in the consumer products division, reflecting a significant increase from \u003cstrong\u003e10%\u003c\/strong\u003e in FY 2022. The digital channel also enables Piramal to enhance its outreach and improve customer engagement.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eOnline Revenue (₹ Crore)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e500\u003c\/td\u003e\n    \u003ctd\u003e10%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e750\u003c\/td\u003e\n    \u003ctd\u003e10%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2023\u003c\/td\u003e\n    \u003ctd\u003e1125\u003c\/td\u003e\n    \u003ctd\u003e15%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eStrategic Alliances\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises has forged several strategic alliances to enhance its market reach and distribution capabilities. Collaborations with major pharmaceutical companies allow access to new markets and broader distribution. For example, in 2023, Piramal entered a partnership with a leading generics manufacturer which is expected to generate an additional \u003cstrong\u003e₹1,200 crore\u003c\/strong\u003e in revenue over the next three years.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, the company has leveraged its strategic partners to expand into emerging markets. The contribution from these alliances has strengthened Piramal’s position, contributing to a revenue growth rate of \u003cstrong\u003e20%\u003c\/strong\u003e in FY 2023 compared to the previous year.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePartnership\u003c\/th\u003e\n    \u003cth\u003eProjected Revenue (₹ Crore)\u003c\/th\u003e\n    \u003cth\u003eYear of Partnership\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLeading Generics Manufacturer\u003c\/td\u003e\n    \u003ctd\u003e1,200\u003c\/td\u003e\n    \u003ctd\u003e2023\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBiopharmaceutical Company\u003c\/td\u003e\n    \u003ctd\u003e800\u003c\/td\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHealthcare Distributor\u003c\/td\u003e\n    \u003ctd\u003e500\u003c\/td\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003ePiramal Enterprises Limited identifies multiple customer segments to effectively deliver its diverse range of products and services.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises caters to a wide array of healthcare providers, including hospitals, clinics, and specialty care facilities. In fiscal year 2023, the company reported a revenue of \u003cstrong\u003e₹12,100 crore\u003c\/strong\u003e from its healthcare business segment, demonstrating a year-over-year growth of \u003cstrong\u003e15%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company's pharmaceutical division includes a focus on essential medicines for hospitals, which now constitutes about \u003cstrong\u003e30%\u003c\/strong\u003e of their total healthcare revenue. In January 2023, Piramal launched a new anesthetic product which is projected to capture a market share of \u003cstrong\u003e10%\u003c\/strong\u003e in the Indian anesthetics market within the next two years.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Investors\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises has positioned itself to attract retail investors through various financial instruments, including fixed deposits, non-convertible debentures (NCDs), and equity shares. As of March 2023, retail investors constituted approximately \u003cstrong\u003e25%\u003c\/strong\u003e of the total shareholding in Piramal Enterprises, with around \u003cstrong\u003e4 lakh\u003c\/strong\u003e individual investors subscribed to NCDs worth \u003cstrong\u003e₹1,500 crore\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company aims to maintain transparency and offers attractive interest rates averaging around \u003cstrong\u003e8-10%\u003c\/strong\u003e per annum for retail investors, enhancing accessibility and trust in its financial products.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises serves numerous pharmaceutical companies, offering contract development and manufacturing services (CDMO). In fiscal year 2023, this segment contributed approximately \u003cstrong\u003e₹3,300 crore\u003c\/strong\u003e in revenue. The company has expanded its API (Active Pharmaceutical Ingredient) services and is involved in over \u003cstrong\u003e100\u003c\/strong\u003e projects with multinational pharma clients.\u003c\/p\u003e\n\u003cp\u003eThe company's robust investment in research and development (R\u0026amp;D) is reflected in its spend of approximately \u003cstrong\u003e₹400 crore\u003c\/strong\u003e in FY 2023, focusing on advanced therapies and formulations. The global CDMO market is set to reach \u003cstrong\u003eUSD 205 billion\u003c\/strong\u003e by 2027, with Piramal targeting a growth rate of \u003cstrong\u003e20%\u003c\/strong\u003e in this sector over the next few years.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eRevenue Contribution (FY 2023)\u003c\/th\u003e\n        \u003cth\u003eYoY Growth\u003c\/th\u003e\n        \u003cth\u003eMarket Share Projection\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n        \u003ctd\u003e₹12,100 crore\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n        \u003ctd\u003e10% in Anesthetics\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRetail Investors\u003c\/td\u003e\n        \u003ctd\u003eNCDs worth ₹1,500 crore\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e25% total shareholding\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Companies\u003c\/td\u003e\n        \u003ctd\u003e₹3,300 crore\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e20% growth target\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePiramal Enterprises efficiently segments its customer base, allowing it to tailor its strategies and enhance overall business performance in rapidly evolving markets.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003ePiramal Enterprises Limited incurs a range of costs essential for its business operations across various sectors, particularly in pharmaceuticals, financial services, and real estate. Understanding these costs is vital for evaluating the company’s financial health and operational efficiency.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003cp\u003eResearch and Development (R\u0026amp;D) is a significant part of Piramal’s strategy, particularly within its pharmaceuticals segment. In FY 2023, the company allocated approximately \u003cstrong\u003eINR 1,200 crore\u003c\/strong\u003e to R\u0026amp;D activities. This represents about \u003cstrong\u003e7.5%\u003c\/strong\u003e of its total revenue, reflecting a commitment to innovation and new product development.\u003c\/p\u003e\n\u003cp\u003eThe company has emphasized developing high-value generics and complex formulations. Notably, R\u0026amp;D spending in previous years has shown a consistent increase, aligning with their goal of enhancing product pipelines and entering new therapeutic areas.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing Expenses\u003c\/h3\u003e\n\u003cp\u003eMarketing expenses are crucial for Piramal’s growth, especially in its pharmaceutical division. In the fiscal year 2023, marketing and promotional expenditure reached around \u003cstrong\u003eINR 500 crore\u003c\/strong\u003e, indicating a focus on expanding market share and product visibility. This amount is approximately \u003cstrong\u003e3.2%\u003c\/strong\u003e of total revenue.\u003c\/p\u003e\n\u003cp\u003eThe company utilizes a mix of digital and traditional marketing strategies to reach healthcare professionals and consumers, thereby enhancing brand awareness and driving sales.\u003c\/p\u003e\n\n\u003ch3\u003eOperational Costs\u003c\/h3\u003e\n\u003cp\u003eOperational costs for Piramal Enterprises include manufacturing, logistics, and administrative expenses. In FY 2023, the operational costs were reported to be approximately \u003cstrong\u003eINR 5,000 crore\u003c\/strong\u003e. The breakdown of these costs is as follows:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCost Type\u003c\/th\u003e\n\u003cth\u003eAmount (INR crore)\u003c\/th\u003e\n\u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n\u003ctd\u003e2,800\u003c\/td\u003e\n\u003ctd\u003e56%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics and Supply Chain\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003ctd\u003e24%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministrative Expenses\u003c\/td\u003e\n\u003ctd\u003e1,000\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe operational costs reflect efficient supply chain management and a focus on cost optimization while maintaining quality in manufacturing. The company has invested in modernizing its facilities to streamline production, which contributes to overall cost efficiency and effectiveness.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003ePiramal Enterprises Limited - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003ePiramal Enterprises Limited operates through various revenue streams, capitalizing on its diversified business operations. The company reports its revenues through numerous segments including product sales, investment income, and licensing fees.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eThe pharmaceutical segment of Piramal Enterprises contributes significantly to its revenue through product sales. For the fiscal year ended March 2023, the pharmaceutical segment generated approximately \u003cstrong\u003e₹2,123 crore\u003c\/strong\u003e, accounting for about \u003cstrong\u003e36%\u003c\/strong\u003e of the total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eInvestment Income\u003c\/h3\u003e\n\u003cp\u003ePiramal Enterprises has a robust financial services division, which provides substantial investment income. In FY2023, investment income was reported at around \u003cstrong\u003e₹1,745 crore\u003c\/strong\u003e, reflecting the company's focus on investment management and financial operations.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Fees\u003c\/h3\u003e\n\u003cp\u003eThe company also earns revenue from licensing fees, primarily through its pharmaceutical segment, where it licenses proprietary products and technologies. In FY2023, licensing fees contributed approximately \u003cstrong\u003e₹550 crore\u003c\/strong\u003e to the total revenues, showcasing a strategic avenue for generating income from intellectual property.\u003c\/p\u003e\n\n\u003ch3\u003eRevenue Summary Table\u003c\/h3\u003e\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Source\u003c\/th\u003e\n        \u003cth\u003eFY2023 Revenue (₹ crore)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduct Sales\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2,123\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e36%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInvestment Income\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1,745\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Fees\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e550\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e9%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOther Income\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1,532\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe combination of these revenue streams illustrates Piramal Enterprises Limited's ability to leverage its diverse portfolio to achieve robust financial performance. The company's strategic focus on pharmaceuticals, financial services, and innovative licensing ensures stability and growth in its revenue generation capabilities.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45756368879765,"sku":"pelns-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/pelns-business-model-canvas.png?v=1739173285","url":"https:\/\/dcf-model.com\/fr\/products\/pelns-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}